
Bristol Myers Squibb Wins EU Approval for Opdivo-Based Lung Cancer Regimen
Bristol Myers Squibb announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for the treatment of resectable non-small cell lung cancer ( …